Javelin Pharmaceuticals (www.javelinpharmaceuticals.com) inked a commercial supply agreement with Precision Pharma Services (www.precisionpharma.com) whereby Precision will manufacture vials of Javelin’s injectable Dyloject™ product (diclofenac sodium 75mg / 2mL) for use in Javelin’s anticipated European markets pending regulatory approval. The agreement has a two-year, renewable term and sets forth minimum purchase and production requirements.
According to Michael Moshman, Javelin’s vp for clinical and commercial manufacturing, “Working with Precision Pharma will enable us to marshal the resources to meet future demand for Dyloject as we begin commercializing this promising analgesic with its launch in the U.K. in 2007.”








This site uses Akismet to reduce spam. Learn how your comment data is processed.